ProMetic Life Sciences Grosses $6.4M From Stock Placement | GenomeWeb
NEW YORK (GenomeWeb News) — ProMetic Life Sciences has closed CA$6.6 million ($6.4 million) by selling 18.9 million subordinate shares for CA$.35 a share, the Montreal-based company said Tuesday.
ProMetic said it issued 13.3 million shares to Paradigm Capital for CA$4.7 million and 5.5 million shares to unidentified US institutional investors for CA$1.9 million.
Rodman & Renshaw Capital Group served as financial advisers for the financing, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.